These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 1489195)
21. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study. Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118 [TBL] [Abstract][Full Text] [Related]
22. Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Sheldon CD; Assoufi BK; Hodson ME Respir Med; 1993 Nov; 87(8):587-93. PubMed ID: 8290742 [TBL] [Abstract][Full Text] [Related]
23. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914 [TBL] [Abstract][Full Text] [Related]
24. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR; Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285 [TBL] [Abstract][Full Text] [Related]
25. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Smith A; Weber A; Pandher R; Williams-Warren J; Cohen ML; Ramsey B Infection; 1997; 25(2):106-8. PubMed ID: 9108186 [TBL] [Abstract][Full Text] [Related]
26. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. Pedersen SS; Jensen T; Hvidberg EF J Antimicrob Chemother; 1987 Oct; 20(4):575-83. PubMed ID: 3479419 [TBL] [Abstract][Full Text] [Related]
27. Altered disposition of fleroxacin in patients with cystic fibrosis. Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750 [TBL] [Abstract][Full Text] [Related]
28. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Bhatt J; Jahnke N; Smyth AR Cochrane Database Syst Rev; 2019 Sep; 9(9):CD002009. PubMed ID: 31483853 [TBL] [Abstract][Full Text] [Related]
29. Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. Schultz AN; Høiby N; Nielsen XC; Pressler T; Dalhoff K; Duno M; Buchard A; Johansen HK; Wang H; Dalbøge CS Pediatr Pulmonol; 2017 Mar; 52(3):319-323. PubMed ID: 28221736 [TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of ciprofloxacin in pediatric patients. Rajagopalan P; Gastonguay MR J Clin Pharmacol; 2003 Jul; 43(7):698-710. PubMed ID: 12856383 [TBL] [Abstract][Full Text] [Related]
31. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Richard DA; Nousia-Arvanitakis S; Sollich V; Hampel BJ; Sommerauer B; Schaad UB Pediatr Infect Dis J; 1997 Jun; 16(6):572-8. PubMed ID: 9194107 [TBL] [Abstract][Full Text] [Related]
32. Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers. Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Kietzig C; Weimann B J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):53-63. PubMed ID: 27448179 [TBL] [Abstract][Full Text] [Related]
33. Treatment of serious infections with intravenous ciprofloxacin. Scully BE; Neu HC Am J Med; 1987 Apr; 82(4A):369-75. PubMed ID: 3555062 [TBL] [Abstract][Full Text] [Related]
34. Use of ciprofloxacin in cystic fibrosis patients. Bosso JA Am J Med; 1989 Nov; 87(5A):123S-127S. PubMed ID: 2589355 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Lettieri JT; Rogge MC; Kaiser L; Echols RM; Heller AH Antimicrob Agents Chemother; 1992 May; 36(5):993-6. PubMed ID: 1510426 [TBL] [Abstract][Full Text] [Related]
36. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Bilton D; Henig N; Morrissey B; Gotfried M Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030 [TBL] [Abstract][Full Text] [Related]